Research Unit of General Practice, Institute of Public Health, University of Southern Denmark.
Pulm Pharmacol Ther. 2011 Dec;24(6):647-53. doi: 10.1016/j.pupt.2011.09.001. Epub 2011 Sep 17.
Studies based on prescription data have shown that many asthmatics tend to use large quantities of inhaled beta-2-agonists, suggesting poorly controlled disease. The aim of the present study was to investigate the association between clinically uncontrolled asthma and prescribing patterns of anti-asthmatic drugs with a primary focus on short-acting beta-2-agonists (SABA).
In a cross-sectional study 357 subjects, selected by their prescriptions of inhaled beta-2-agonists in Odense Pharmaco-Epidemiological Database, underwent individual clinical assessment including the Asthma Control Questionnaire (ACQ) and spirometry. The associations between uncontrolled asthma (ACQ score ≥ 1.50) and individual anti-asthmatic prescribing were analysed by means of logistic regression.
Clinically uncontrolled asthma was positively associated with SABA use, the association becoming stronger with higher annual quantity of SABA use, odds ratio (OR) 11.1 (95% CI 4.4-28.0) for ≥400 DDD/year. This trend persisted after stratifying for gender, age, and controller treatment. Although subjects using ≥450 DDD/year were all uncontrolled, there was substantial overlap in SABA use between controlled and uncontrolled subjects below this limit. We found no effect modification by age and gender. Use of inhaled corticosteroids protected against uncontrolled asthma, OR 0.51 (95% CI 0.27-0.95).
Asthmatics with a high use of SABA frequently have problems with uncontrolled asthma, and users of ICS are protected against uncontrolled asthma. The associations we found were, however, to weak too allow firm conclusions about asthma control for most individual asthma patients.
基于处方数据的研究表明,许多哮喘患者倾向于使用大量吸入性β2-受体激动剂,提示疾病控制不佳。本研究旨在探讨临床未控制哮喘与抗哮喘药物处方模式之间的关系,重点关注短效β2-受体激动剂(SABA)。
在一项横断面研究中,357 名受试者根据其在奥登塞药物流行病学数据库中吸入性β2-受体激动剂的处方选择,接受了个体临床评估,包括哮喘控制问卷(ACQ)和肺量测定。采用逻辑回归分析未控制哮喘(ACQ 评分≥1.50)与个体抗哮喘药物处方之间的关系。
临床未控制哮喘与 SABA 使用呈正相关,随着 SABA 年用量的增加,相关性增强,SABA 年用量≥400 DDD 的比值比(OR)为 11.1(95%CI 4.4-28.0)。在按性别、年龄和控制器治疗分层后,这种趋势仍然存在。尽管使用≥450 DDD/年的患者均未得到控制,但在该限值以下,控制和未控制患者之间在 SABA 使用方面存在大量重叠。我们未发现年龄和性别对结果有修饰作用。吸入皮质激素的使用可预防未控制的哮喘,OR 为 0.51(95%CI 0.27-0.95)。
高剂量使用 SABA 的哮喘患者常出现未控制哮喘的问题,而使用 ICS 的患者则可预防未控制的哮喘。然而,我们发现的相关性太弱,无法对大多数个体哮喘患者的哮喘控制做出明确结论。